An Indian scientist works inside a laboratory of the Research and Development Centre of Natco Pharma Ltd. in Hyderabad, India, Tuesday, March 13, 2012. India effectively ended Bayer's monopoly on a patented cancer drug Monday, licensing a much cheaper generic under a unique law aimed at keeping costs affordable. In a decision likely to upset Western pharmaceuticals, the patent office approved Natco Pharma Ltd.'s application to produce the kidney and liver cancer treatment sorefinib.

An Indian scientist works inside a laboratory of the Research and Development Centre of Natco Pharma Ltd. in Hyderabad, India, Tuesday, March 13, 2012. India effectively ended Bayer's monopoly on a patented cancer drug Monday, licensing a much cheaper generic under a unique law aimed at keeping costs affordable. In a decision likely to upset Western pharmaceuticals, the patent office approved Natco Pharma Ltd.'s application to produce the kidney and liver cancer treatment sorefinib.

Generic drugs account for 80 percent of the pharmaceuticals prescribed to Americans. Why they’re cheaper and who’s responsible when something goes wrong.

Guests

  • Katie Thomas reporter, New York Times
  • Steven Brill journalist and author of "Bitter Pill: How outrageous pricing and egregious profits are destroying our health care," a special report for Time Magazine's March 4, 2013, edition.
  • Dr. Sidney Wolfe director of the Health Research Group at Public Citizen; editor of WorstPills.org
  • Ralph Neas president and ceo, Generic Pharmaceutical Association

Topics + Tags

Comments

comments powered by Disqus
Most Recent Shows

Why We Doubt Scientific Findings

Wednesday, Mar 04 2015We live in an age when science and technology touch nearly every aspect of our lives. Yet scientific findings on climate change, vaccines and evolution are increasingly under attack. Why people doubt science.

King v. Burwell And The Future Of Obamacare

Tuesday, Mar 03 2015The Supreme Court takes up a major challenge to the Affordable Care Act this week. The ruling could make health insurance unaffordable for millions of Americans. We take a look at King v. Burwell and the future of the ACA.